Brief Summary

Bimatoprost has been shown to provide effective IOP lowering in patients of all races. Conversely, travoprost has been shown to be more effective in black patients than in Caucasians in some studies. However, Noecker et al 2004 compared bimatoprost with travoprost in African-Americans with glaucoma or OHT, and found that bimatoprost was more likely than travoprost to achieve target pressure at 3 months. These racial differences in efficacy of these medications warrant further investigations. The investigators study aim to compare the IOP-lowering efficacies of bimatoprost and travoprost in an Egyptian population with primary open-angle glaucoma (OAG) or ocular hypertension (OHT).

Trial Health

On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach

1 country

1 active site

Status

completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 23, 2010

Completed

1 day until next milestone

First Posted

Study publicly available on registry

March 24, 2010

Completed

Last Updated

March 24, 2010

Status Verified

January 1, 2008

First QC Date

March 23, 2010

Last Update Submit

March 23, 2010

Conditions

Glaucoma Ocular Hypertension

Keywords

Glaucoma and Ocular Hypertension

Outcome Measures

Primary Outcomes (1)

Percentage of intraocular pressure lowering of bimatoprost versus travoprost.

Secondary Outcomes (1)

Rate of development of complications.

Study Arms (1)